Omeros (OMER) Shares Up 7.8%

Omeros Co. (NASDAQ:OMER) shares shot up 7.8% during mid-day trading on Thursday . The company traded as high as $16.71 and last traded at $16.34. 690,355 shares traded hands during trading, a decline of 32% from the average session volume of 1,021,658 shares. The stock had previously closed at $15.16.

Several research analysts have recently weighed in on the company. ValuEngine upgraded Omeros from a “hold” rating to a “buy” rating in a research note on Friday, October 19th. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, July 18th. HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Omeros in a research note on Thursday, June 28th. Finally, BidaskClub upgraded Omeros from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $27.56.

The stock has a market cap of $748.79 million, a P/E ratio of -20.09 and a beta of 3.49. The company has a quick ratio of 3.94, a current ratio of 3.95 and a debt-to-equity ratio of -2.31.



Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $1.84 million. The business’s revenue was down 90.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.33) EPS. On average, analysts expect that Omeros Co. will post -2.48 earnings per share for the current fiscal year.

In related news, VP Marcia S. Kelbon sold 7,529 shares of the company’s stock in a transaction on Friday, August 31st. The stock was sold at an average price of $25.75, for a total transaction of $193,871.75. Following the completion of the sale, the vice president now owns 227,645 shares in the company, valued at $5,861,858.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.10% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Ingalls & Snyder LLC grew its holdings in Omeros by 1.3% during the second quarter. Ingalls & Snyder LLC now owns 5,613,487 shares of the biopharmaceutical company’s stock valued at $101,829,000 after purchasing an additional 70,625 shares during the period. BlackRock Inc. grew its holdings in Omeros by 0.9% during the first quarter. BlackRock Inc. now owns 3,965,410 shares of the biopharmaceutical company’s stock valued at $44,294,000 after purchasing an additional 34,832 shares during the period. Cpwm LLC grew its holdings in Omeros by 5.0% during the second quarter. Cpwm LLC now owns 1,074,543 shares of the biopharmaceutical company’s stock valued at $19,492,000 after purchasing an additional 51,015 shares during the period. Northern Trust Corp grew its holdings in Omeros by 2.1% during the second quarter. Northern Trust Corp now owns 615,377 shares of the biopharmaceutical company’s stock valued at $11,162,000 after purchasing an additional 12,827 shares during the period. Finally, Millennium Management LLC bought a new stake in Omeros during the second quarter valued at about $8,513,000. Institutional investors own 48.14% of the company’s stock.

About Omeros (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: What are trading strategies for the 52-week high/low?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply